
Expand access to cardiometabolic care across international markets
Arcera Life Sciences, an international life sciences company headquartered in Abu Dhabi, UAE, and Innogen Pharmaceuticals, a Shanghai-based biopharmaceutical company focused on metabolic diseases, have announced an exclusive licensing and commercialization agreement for Efsubaglutide Alfa, a GLP-1 receptor agonist therapy across key international markets, including the UAE.
The agreement brings together Innogen’s expertise in metabolic diseases with Arcera’s regulatory, market access and commercial capabilities, establishing cardiometabolic disease as a core pillar of Arcera’s portfolio. It also reflects Arcera’s ambition to be a partner of choice for bringing differentiated innovative medicines to patients in international markets.
Under the agreement, Arcera will be responsible for regulatory activities, market access and commercialization of the therapy across agreed territories spanning selected countries in Africa, Eastern Europe, Latin America and the Middle East. Innogen will receive an upfront payment and will be eligible for milestone payments and tiered royalties on net sales of the product in the licensed territories.
GLP-1 receptor agonists are a class of therapy used in the management of type 2 diabetes and, increasingly, obesity. In 2025, the World Health Organization added GLP-1 therapies to its Model List of Essential Medicines and issued a global guideline on their use in treating obesity, a condition affecting more than one billion people worldwide.
Further growth
For Arcera, the agreement strengthens its presence in this therapy area and creates a platform for further growth in cardiometabolic medicine across its international markets.
“By combining our partners’ scientific capabilities with Arcera’s regulatory expertise, market access and overall commercial reach, we aim to turn innovation into meaningful impact for people living with chronic disease,” commented Isabel Afonso, Chief Executive Officer, Arcera Life Sciences.
“Our collaboration with Arcera is an important step toward this vision. By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world,” added Dr. Qinghua Wang, Founder, Chairman and Chief Executive Officer, Innogen Pharmaceuticals.
